<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856752</url>
  </required_header>
  <id_info>
    <org_study_id>NRL972-04A/2005 (IN-A)</org_study_id>
    <nct_id>NCT00856752</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine</brief_title>
  <official_title>A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part A: Interaction With Rifampicin and Cyclosporine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy volunteers to determine whether different drugs metabolised by the liver
      have any effects on how NRL972 is processed within the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total clearance by non-compartmental analysis. Apparent terminal disposition half-life tÂ½ by non-compartmental analysis</measure>
    <time_frame>Up to 6 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-compartmental PK-analysis based on the extensive profile (up to last quantifiable data point), the 'short' profile (over the first hour after injection), and the two-point profile based on selected data-pairs over the 1st hour after dosing</measure>
    <time_frame>Up to 6 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with rifampicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment with cyclosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of NRL001 alone: no pre-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Reference test: Single intravenous administration of 2 mg NRL972</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females (females of non-childbearing potential or of childbearing potential
             while taking medically appropriate contraception)

          2. Caucasian

          3. Age: 21 - 40 years

          4. BW 50 - 100 kg

          5. BMI 20 - 26 kg.m-2

          6. healthy based on the pre-study examination

          7. willing and able to provide informed consent

        Exclusion Criteria:

        General - all subjects

          1. Previous participation in the trial

          2. Participant in any other trial during the last 90 days

          3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL
             within the last 3 months

          4. History of any clinically relevant allergy (including hypersensitivity to the trial
             medications)

          5. Presence of acute or chronic infection

          6. Presence or history of any relevant co-morbidity

          7. Resting systolic blood pressure &gt; 160 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or &lt;
             50 mmHg

          8. Clinically relevant ECG-abnormalities, prolonged QTc with &gt; 450 msec in males and &gt;
             460 msec in females in particular

          9. Presence of any relevant abnormality in the laboratory safety tests, especially low
             haemoglobin, increased liver enzymes

         10. Positive serology for HBsAg, anti HBc and anti HCV

         11. Positive HIV test

         12. Positive alcohol or urine drug test on recruitment (and upon admission)

         13. History of alcohol and/or drug abuse and/or daily use of &gt; 30 gr alcohol

         14. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

         15. Use of prohibited medication

         16. Suspicion or evidence that the subject is not trustworthy and reliable

         17. Suspicion or evidence that the subject is not able to make a free consent or to
             understand the information in this regard

             General - all females

         18. Positive pregnancy test

         19. Lactating

         20. Not using appropriate contraception in pre-menopausal women (note: under the
             conditions of the present study, women using hormonal contraceptives will be informed
             that this method is not sufficient during the study and that further i.e. mechanical
             methods [condom, diaphragm with spermacide gel] should be used in addition).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans J Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emil Gatchev, PD Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>MHAPT &quot;Zaritza Johanna&quot; University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Clinical Pharmacology &amp; Therapeutics, MHAPT &quot;Zaritza Johanna&quot; University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

